Enzalutamide, a potent oral androgen receptor inhibitor, improves survival in men with metastatic castration-resistant prostate cancer (CRPC) before and after chemotherapy. Bicalutamide, a ...
Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial In men with prostate cancer, bicalutamide monotherapy increases bone mineral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results